Aldevron Breakthrough Blog

Shining a Light on Rare Diseases

February 21, 2022 / by Sharon King

Don't let the word "rare" fool you. While there are more than 7,000 rare diseases, the collective number of people impacted by them adds up to the same amount as those facing type 2 diabetes.

Despite the fact most people will not face the challenges of living with a rare diagnosis; significant effects of rare diseases run broad and deep around the world. The economic burden in the United States alone is estimated at more than $1 trillion each year.

Four independent studies provide evidence of the need for:

Rare Disease Day, always the last day of February, shows our support and shines a light on the challenges faced by this fearless community.

We are in unprecedented times of innovation for rare diseases and the patient voice remains as critical as it always has. Much of our work at Aldevron is dedicated to these breakthroughs which requires strong and committed partners who understand the challenges and urgency of patients and families living with rare diagnoses – diseases that have few or no options.

Most of all, it calls for a willingness to work together to achieve the ultimate goal, which is also our mission: to make lives better. That mission is always our guiding light, but it shines even brighter each year on Rare Disease Day.

Don't let the word rare fool you. Rare is everywhere.

ABOUT THE AUTHOR

Sharon King

Sharon King

Sharon King joined Aldevron in 2019 as Advocacy and Community Engagement Manager for the GMP Nucleic Acids Business Unit. In this role, Sharon helps drive Aldevron’s mission of service through making lives better, representing “high-touch” in this high-tech world supporting genetic medicine by focusing on internal team member education. She also works collaboratively with clients’ patient advocate teams to understand disease targets and, most importantly, the population of individuals and caregivers potentially impacted by their innovations. Sharon is a thought leader who has united public officials, researchers, biotech and industry representatives, and patient advocates to progress rare disease treatment development. She co-founded Taylor’s Tale in 2006 to support the development and implementation of innovative treatments for CLN1 disease, as well as programs and public policies that improve quality of life for rare disease patients and their families. Sharon holds a Bachelor of Music in Piano Performance and is a state-appointed member of the N.C. Rare Disease Advisory Council.